Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
Karlyn A MartinJan Beyer-WestendorfBruce L DavidsonMenno V HuismanPer Morten SandsetStephan MollPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and prevention in patients with obesity, including phase 3, phase 4, meta-analyses, and pharmacokinetic and pharmacodynamics studies. In addition, we reviewed available data regarding DOACs in bariatric surgery. We provide updated guidance recommendations on using DOACs in patients with obesity for treatment and prevention of VTE, as well as following bariatric surgery.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- bariatric surgery
- weight loss
- insulin resistance
- metabolic syndrome
- type diabetes
- atrial fibrillation
- systematic review
- randomized controlled trial
- weight gain
- oral anticoagulants
- high fat diet induced
- skeletal muscle
- big data
- adipose tissue
- physical activity
- replacement therapy